about
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsExpression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer.DNA methylation profiling in doxorubicin treated primary locally advanced breast tumours identifies novel genes associated with survival and treatment response.Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy.Glomeruloid microvascular proliferation is associated with lack of response to chemotherapy in breast cancerSubclonal diversification of primary breast cancer revealed by multiregion sequencing.Evaluation of Tumor Cell Proliferation by Ki-67 Expression and Mitotic Count in Lymph Node Metastases from Breast Cancer.Extra-nodal extension is a significant prognostic factor in lymph node positive breast cancer.Absence of p21 expression is associated with abnormal p53 in human breast carcinomas.Plasma insulin-like growth factor binding protein-3 proteolysis is increased in primary breast cancer.Serum concentrations of tamoxifen and its metabolites increase with age during steady-state treatment.Tumour cell invasion into blood vessels is significantly related to breast cancer subtypes and decreased survival.Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer.Microvessel proliferation by co-expression of endothelial nestin and Ki-67 is associated with a basal-like phenotype and aggressive features in breast cancer.Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status.[Breast-preserving surgery in breast cancer. Experiences from Haukeland Hospital 1983-1988]Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy.TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer.Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels.[Breast conserving surgery in breast cancer. Experiences from the Haukeland Hospital 1983-88]Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status.Fatigue, anxiety and depression overrule the role of oncological treatment in predicting self-reported health complaints in women with breast cancer compared to healthy controls.Diet in women with breast cancer compared to healthy controls - What is the difference?Increase of endo-peptidases and exo-peptidases in thyroid-tumors.Lack of diagnostic-value of DNA content and p53 immunostaining in normal, hyperplastic and neoplastic parathyroid tissue.Illness uncertainty in breast cancer patients: validation of the 5-item short form of the Mishel Uncertainty in Illness Scale.Jan Erik Varhaug.Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer.[Breast sarcoma. Diagnostic and therapeutic problems]Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients[Primary treatment of locally advanced breast cancer with neoadjuvant chemotherapy]Progesterone binding cyst protein in hormone receptor positive breast cancer; a predictive factor for effect of adjuvant tamoxifen treatmentAngiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancerPrimary systemic treatment with weekly doxorubicin monotherapy in women with locally advanced breast cancer; clinical experience and parameters predicting outcome
P50
Q27860709-14E5FC4D-2665-4F75-BCF4-8A619137043FQ30491493-61CF7E71-1AB3-43D8-9654-6F7BBEFB5D76Q33816178-B2DA0681-D474-4797-B8C6-F6515768D7F1Q33893910-9F8C0197-FD29-4A8C-A641-882597B899E1Q34576275-0775E13D-9488-4B9F-9C4D-9DED42559D7FQ35108398-576ABFD8-0175-442E-8A34-81D001E56EBAQ35847434-5332501D-6324-472D-8157-7CE824F879E8Q35949311-E01610AA-6719-4AB7-90D8-BA238E6D2846Q36281258-E3264EB0-B407-498F-A3A7-6CC3A7D8B294Q36430949-938A0266-90A2-4DEB-9A29-7725E3C8DAFAQ36623079-F6AC0AC6-020E-417A-9C1E-1E35A2A46454Q37202495-6212D5E9-B28E-49EE-BD75-DBCD5ADFAE44Q40587917-A4B7772A-1F31-4110-823F-BC87C22BA632Q40907746-7A96F948-E7E1-496F-8F7D-C651182E62D2Q42491095-78B82123-575D-4C06-9FC8-B163A1262FAAQ42510283-E1788FAE-162D-453E-8DDD-946740959509Q43250234-23E3CC72-BEDC-4937-906D-2F7247FC8965Q44236063-07B6E60F-AD5A-46B0-AFBA-5066AE1C4A51Q44443788-D1BC9D41-1839-4906-AE2B-72EFF1C3A132Q44679253-413B4531-E0A3-44B8-A0B0-64016E8D449CQ44893183-EFA18715-D273-4329-BB45-6A59D99CFF87Q45003549-B48245C6-FB13-468D-AE23-2F5D2E1242FCQ45932609-6F8067AD-2091-47AE-A815-7239A8EE8F18Q47423621-8183D035-28B3-431D-86D2-2A416F9E678AQ47550979-B942F9AE-500A-49C1-9025-49F7247A5CB8Q47756549-8660FABB-1AF0-4894-8D7B-D29DE2CB8C69Q47757169-55C7F763-6461-4165-918F-679B7CBF601BQ47768204-5E097B80-9FE6-4BAD-B281-2B71F639FD77Q49821151-47D4D07E-2D94-420E-ADE3-D2AEDF514E3BQ52542729-034C7BBD-C2CB-4DCC-A431-1A4D3B35D2F3Q69660289-7373CFE2-8617-48A7-A6D0-999449F8125EQ71169983-E8D9F794-E7CF-4900-AB04-BB7029047DDBQ72443949-76AA6ACE-3325-4F47-A24B-9F9ADB2252F4Q72493581-80874D47-DB9D-4560-9D56-F134A0F55962Q73081874-2C2E615F-800F-49C4-B56A-793ED028FF49Q73322847-94F23E86-CE6F-45FC-A8C9-61BCD0A032BE
P50
description
Noors onderzoekster
@nl
Norwegian researcher
@en
norsk forsker
@nb
name
Turid Aas
@da
Turid Aas
@de
Turid Aas
@en
Turid Aas
@es
Turid Aas
@fr
Turid Aas
@nb
Turid Aas
@nl
Turid Aas
@nn
Turid Aas
@sl
Turid Aas
@sv
type
label
Turid Aas
@da
Turid Aas
@de
Turid Aas
@en
Turid Aas
@es
Turid Aas
@fr
Turid Aas
@nb
Turid Aas
@nl
Turid Aas
@nn
Turid Aas
@sl
Turid Aas
@sv
prefLabel
Turid Aas
@da
Turid Aas
@de
Turid Aas
@en
Turid Aas
@es
Turid Aas
@fr
Turid Aas
@nb
Turid Aas
@nl
Turid Aas
@nn
Turid Aas
@sl
Turid Aas
@sv